Targeted therapies such as C5 inhibitors and neonatal Fc receptor antagonists have demonstrated the potential for sustained improvements in the clinical manifestations of MG that may in turn facilitate CS tapering or discontinuation [20, 28–31]. Here, C5 is linked to myasthenia gravis.